Your browser doesn't support javascript.
loading
A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.
Jang, H Josh; Hostetter, Galen; Macfarlane, Alexander W; Madaj, Zachary; Ross, Eric A; Hinoue, Toshinori; Kulchycki, Justin R; Burgos, Ryan S; Tafseer, Mahvish; Alpaugh, R Katherine; Schwebel, Candice L; Kokate, Rutika; Geynisman, Daniel M; Zibelman, Matthew R; Ghatalia, Pooja; Nichols, Peter W; Chung, Woonbok; Madzo, Jozef; Hahn, Noah M; Quinn, David I; Issa, Jean-Pierre J; Topper, Michael J; Baylin, Stephen B; Shen, Hui; Campbell, Kerry S; Jones, Peter A; Plimack, Elizabeth R.
Afiliação
  • Jang HJ; Department of Epigenetics, Van Andel Institute, Grand Rapids, Michigan.
  • Hostetter G; Pathology and Biorepository Core, Van Andel Institute, Grand Rapids, Michigan.
  • Macfarlane AW; Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Madaj Z; Bioinformatics & Biostatistics Core, Van Andel Institute, Grand Rapids, Michigan.
  • Ross EA; Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Hinoue T; Department of Epigenetics, Van Andel Institute, Grand Rapids, Michigan.
  • Kulchycki JR; Department of Epigenetics, Van Andel Institute, Grand Rapids, Michigan.
  • Burgos RS; Department of Epigenetics, Van Andel Institute, Grand Rapids, Michigan.
  • Tafseer M; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Alpaugh RK; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Schwebel CL; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Kokate R; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Geynisman DM; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Zibelman MR; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Ghatalia P; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Nichols PW; Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, California.
  • Chung W; The Coriell Institute for Medical Research, Camden, New Jersey.
  • Madzo J; The Coriell Institute for Medical Research, Camden, New Jersey.
  • Hahn NM; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland.
  • Quinn DI; University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine of USC, Los Angeles, California.
  • Issa JJ; The Coriell Institute for Medical Research, Camden, New Jersey.
  • Topper MJ; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland.
  • Baylin SB; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland.
  • Shen H; Department of Epigenetics, Van Andel Institute, Grand Rapids, Michigan.
  • Campbell KS; Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
  • Jones PA; Department of Epigenetics, Van Andel Institute, Grand Rapids, Michigan.
  • Plimack ER; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Clin Cancer Res ; 29(11): 2052-2065, 2023 06 01.
Article em En | MEDLINE | ID: mdl-36928921
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Carcinoma de Células de Transição / Antineoplásicos Limite: Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Carcinoma de Células de Transição / Antineoplásicos Limite: Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article